Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)
CANNANNEW REPORT

SAN FRANCISCO–(BUSINESS WIRE)–#GPCR–Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced that it has entered into the clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), a leader in immuno-oncology (IO). […]

Excerpt only …
READ MORE BELOW
Source : Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)

reposted by Cannabis News World